TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest announcement is out from SCYNEXIS ( (SCYX) ).
On June 20, 2025, SCYNEXIS received a notification from Nasdaq regarding its failure to meet the minimum bid price requirement for its common stock, which has been below $1.00 for 30 consecutive business days. SCYNEXIS has until December 17, 2025, to regain compliance, with options including a reverse stock split if necessary. Failure to comply could result in delisting, although SCYNEXIS may appeal any delisting decision.
The most recent analyst rating on (SCYX) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on SCYNEXIS stock, see the SCYX Stock Forecast page.
Spark’s Take on SCYX Stock
According to Spark, TipRanks’ AI Analyst, SCYX is a Neutral.
The overall stock score for SCYX is primarily influenced by poor financial performance and valuation metrics. The technical analysis reflects bearish sentiment, further affecting the score. The absence of a dividend and negative earnings contribute to a challenging valuation environment.
To see Spark’s full report on SCYX stock, click here.
More about SCYNEXIS
SCYNEXIS, Inc. operates in the pharmaceutical industry, focusing on the development and commercialization of novel anti-infectives to address significant unmet therapeutic needs.
Average Trading Volume: 133,255
Technical Sentiment Signal: Sell
Current Market Cap: $29.23M
Learn more about SCYX stock on TipRanks’ Stock Analysis page.